<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JACC Adv</journal-id><journal-id journal-id-type="iso-abbrev">JACC Adv</journal-id><journal-title-group><journal-title>JACC: Advances</journal-title></journal-title-group><issn pub-type="epub">2772-963X</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40286379</article-id><article-id pub-id-type="pmc">PMC12103075</article-id><article-id pub-id-type="pii">S2772-963X(25)00145-0</article-id><article-id pub-id-type="doi">10.1016/j.jacadv.2025.101728</article-id><article-id pub-id-type="publisher-id">101728</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Investigating the Anrep Effect in Hypertrophic Obstructive Cardiomyopathy With Invasive Pressure-Volume Analysis</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Reil</surname><given-names>Jan-Christian</given-names></name><degrees>MD</degrees><email>jreil@hdz-nrw.de</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref><xref rid="fn1" ref-type="fn">&#x02217;</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Sequeira</surname><given-names>Vasco</given-names></name><degrees>PhD</degrees><email>Sequeira_V@ukw.de</email><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor2" ref-type="corresp">&#x02217;&#x02217;</xref><xref rid="fn1" ref-type="fn">&#x02217;</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Reil</surname><given-names>Gert-Hinrich</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Scholtz</surname><given-names>Smita</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Rudolph</surname><given-names>Volker</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Maack</surname><given-names>Christoph</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Serruys</surname><given-names>Patrick</given-names></name><degrees>MD</degrees><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Steendijk</surname><given-names>Paul</given-names></name><degrees>PhD</degrees><xref rid="aff5" ref-type="aff">e</xref></contrib><aff id="aff1"><label>a</label>Klinik f&#x000fc;r allgemeine und interventionelle Kardiologie, Herz-und Diabetes Zentrum Nordrhein-Westphalen, Bad Oeynhausen, Germany</aff><aff id="aff2"><label>b</label>Comprehensive Heart Failure Center, University Clinic W&#x000fc;rzburg, W&#x000fc;rzburg, Germany</aff><aff id="aff3"><label>c</label>Universit&#x000e4;tsklinik f&#x000fc;r Innere Medizin&#x02013;Kardiologie, Klinikum Oldenburg, Oldenburg, Germany</aff><aff id="aff4"><label>d</label>CORRIB Research Centre for Advanced Imaging and Core Laboratory, University of Galway, Galway, Ireland</aff><aff id="aff5"><label>e</label>Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label><bold>Address for correspondence:</bold> Dr Jan-Christian Reil, Klinik f&#x000fc;r allgemeine und interventionelle Kardiologie, Herz-und Diabetes Zentrum-NRW, Georgstrasse 11, 32545 Bad Oeynhausen, Germany. <email>jreil@hdz-nrw.de</email></corresp><corresp id="cor2"><label>&#x02217;&#x02217;</label>Dr Vasco Sequeira, Department of Translational Science, University Clinic W&#x000fc;rzburg, Am Schwarzenberg 15, 97078 W&#x000fc;rzburg, Germany. <email>Sequeira_V@ukw.de</email></corresp><fn id="fn1"><label>&#x02217;</label><p id="ntpara0010">These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>25</day><month>4</month><year>2025</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>25</day><month>4</month><year>2025</year></pub-date><volume>4</volume><issue>5</issue><elocation-id>101728</elocation-id><history><date date-type="received"><day>18</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>21</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><sec><title>Background</title><p>The Anrep effect, an adaptation enhancing left ventricular (LV) contractility in response to raised afterload, is hypothesized to influence hypertrophic cardiomyopathy pathophysiology.</p></sec><sec><title>Objectives</title><p>This study investigated the activation and reversibility of the Anrep effect in obstructive hypertrophic cardiomyopathy (HOCM) patients undergoing percutaneous transluminal septal myocardial ablation (PTSMA) to relieve LV outflow tract obstruction.</p></sec><sec><title>Methods</title><p>Invasive pressure-volume (PV) analysis was performed on 14 HOCM patients before and after PTSMA. The &#x0201c;Anrep Triad,&#x0201d; defined by elevated afterload (higher LV end-systolic pressure and effective arterial elastance), augmented contractility (higher end-systolic elastance and maximum LV pressure rise [dP/dt<sub>max</sub>]), and prolonged systolic duration (dTes), was assessed via direct hemodynamic comparison preprocedure and postprocedure. Stroke work (SW), potential energy, and total PV area (PVA) quantified mechanical work and efficiency (SW/PVA).</p></sec><sec><title>Results</title><p>Postprocedure reversal of the Anrep effect was confirmed (pre- vs post-PTSMA), with reductions in afterload (LV end-systolic pressure: 180 vs 138&#x000a0;mm&#x000a0;Hg, <italic>P</italic>&#x000a0;=&#x000a0;0.0001; effective arterial elastance: 2.5 vs 1.9&#x000a0;mm&#x000a0;Hg/mL, <italic>P</italic>&#x000a0;=&#x000a0;0.002), contractility (end-systolic elastance: 2.0 vs 1.5&#x000a0;mm&#x000a0;Hg/mL, <italic>P</italic>&#x000a0;=&#x000a0;0.0001; dP/dt<sub>max:</sub> 1,775 vs 1,560&#x000a0;mm&#x000a0;Hg/s, <italic>P</italic>&#x000a0;=&#x000a0;0.017), and systolic duration (dTes: 371 vs 327&#x000a0;ms, <italic>P</italic>&#x000a0;=&#x000a0;0.002). Preprocedure, HOCM patients exhibited higher mechanical workload (SW: 8,161 vs 7,495&#x000a0;mm&#x000a0;Hg&#x000b7;mL, <italic>P</italic>&#x000a0;=&#x000a0;0.004; potential energy: 7,837 vs 4,915&#x000a0;mm&#x000a0;Hg&#x000b7;mL, <italic>P</italic>&#x000a0;=&#x000a0;0.002; PVA: 16,135 vs 11,742&#x000a0;mm&#x000a0;Hg&#x000b7;mL, <italic>P</italic>&#x000a0;=&#x000a0;0.0002) and lower efficiency (SW/PVA: 50% vs 59%, <italic>P</italic>&#x000a0;=&#x000a0;0.03).</p></sec><sec><title>Conclusions</title><p>The Anrep effect is an energy-demanding compensatory mechanism that maintains stroke volume under elevated afterload by increasing contractility and prolonging systole. This study confirms its chronic activation in HOCM and its immediate reversal post-PTSMA.</p></sec></abstract><abstract abstract-type="graphical" id="abs0015"><title>Central Illustration</title><fig id="undfig1" position="anchor"><graphic xlink:href="ga1"/></fig></abstract><kwd-group id="kwrds0010"><title>Key words</title><kwd>hypertrophic obstructive cardiomyopathy</kwd><kwd>Anrep effect</kwd><kwd>afterload</kwd><kwd>Anrep triad</kwd><kwd>septal ablation</kwd></kwd-group></article-meta><def-list><title>Abbreviations and Acronyms</title><def-item><term id="kwrd0040">dP/dt<sub>max</sub></term><def><p>maximum rate of left ventricular pressure rise</p></def></def-item><def-item><term id="kwrd0050">dTdPdt</term><def><p>time between dP/dt<sub>max</sub> and dP/dt<sub>min</sub></p></def></def-item><def-item><term id="kwrd0060">dTes</term><def><p>duration of systole</p></def></def-item><def-item><term id="kwrd0070">Ea</term><def><p>effective arterial elastance</p></def></def-item><def-item><term id="kwrd0080">EDPVR</term><def><p>end-diastolic pressure-volume relationship</p></def></def-item><def-item><term id="kwrd0090">EDV</term><def><p>end-diastolic volume</p></def></def-item><def-item><term id="kwrd0100">Ees</term><def><p>end-systolic elastance</p></def></def-item><def-item><term id="kwrd0110">ESPVR</term><def><p>end-systolic pressure-volume relationship</p></def></def-item><def-item><term id="kwrd0120">ESV</term><def><p>end-systolic volume</p></def></def-item><def-item><term id="kwrd0130">HOCM</term><def><p>hypertrophic obstructive cardiomyopathy</p></def></def-item><def-item><term id="kwrd0140">LV</term><def><p>left ventricular</p></def></def-item><def-item><term id="kwrd0150">LVESP</term><def><p>left ventricular end-systolic pressure</p></def></def-item><def-item><term id="kwrd0160">LVOTO</term><def><p>left ventricular outflow tract obstruction</p></def></def-item><def-item><term id="kwrd0170">PE</term><def><p>potential energy</p></def></def-item><def-item><term id="kwrd0180">PV</term><def><p>pressure-volume</p></def></def-item><def-item><term id="kwrd0190">PTSMA</term><def><p>percutaneous transluminal septal myocardial ablation</p></def></def-item><def-item><term id="kwrd0200">PVA</term><def><p>total pressure-volume area</p></def></def-item><def-item><term id="kwrd0210">SAM</term><def><p>systolic anterior motion</p></def></def-item><def-item><term id="kwrd0220">SW</term><def><p>stroke work</p></def></def-item></def-list></front><body><p id="p0010">Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease, characterized by left ventricular (LV) hypertrophy. Diagnosis is based on an end-diastolic LV wall thickness of at least 15&#x000a0;mm, or 13 to 14&#x000a0;mm in individuals with a family history of HCM or a positive genetic test.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Despite established genetic links to mutations in various sarcomeric genes, nearly 65% of symptomatic patients lack these common pathogenic variants.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Key features of HCM include hyperdynamic systolic function, diastolic dysfunction, and significant hypertrophy of the interventricular septum, often accompanied by mitral valve abnormalities.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> These frequently lead to LV outflow tract obstruction (LVOTO) in up to two-thirds of patients, primarily due to systolic anterior motion (SAM) of the mitral valve.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> LVOTO increases afterload, raises LV end-systolic pressure (LVESP), and exacerbates hypercontractility, myocardial oxygen consumption, diastolic dysfunction, secondary mitral regurgitation, and the risk of heart failure and sudden cardiac death.<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref> Clinically, LVOTO is associated with symptoms like exercise intolerance, dyspnea, fatigue, and syncope.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> Treatments such as septal myectomy or percutaneous transluminal septal myocardial ablation (PTSMA) are the primary methods to alleviate LVOTO and reduce afterload.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> Patients with HCM and LVOTO are classified as having hypertrophic obstructive cardiomyopathy (HOCM). Our previous research hinted at a link between chronic high afterload from LVOTO and hyperdynamic contraction, potentially due to the prolonged activation of the Anrep effect in HOCM.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref></p><p id="p0015">Historically viewed as a transient, nonpathological adaptation, the Anrep effect augments LV contractility in response to the sudden rise in afterload.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> Although its physiological importance is well-documented, its clinical relevance has largely gone unrecognized. Using the working heart approach in isolated healthy mouse hearts, we previously characterized the Anrep effect's hemodynamic signature during acute afterload elevations at constant preload and heart rate.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> This signature is summarized by a triad of responses: 1) elevated afterload, indicated by high LVESP; 2) increased contractility, shown by a leftward shift of end-systolic pressure-volume relationship (ESPVR) with a steepened slope (end-systolic elastance [Ees]), and increased maximum rate of LV pressure rise (dP/dt<sub>max</sub>); and 3) prolonged duration of systole (dTes).<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> This transient effect is reversible when afterload normalizes.</p><p id="p0020">In this study, we investigate the hemodynamic signature of the Anrep effect&#x02014;increased contractility and prolonged systole in response to elevated afterload from LVOTO&#x02014;and its reversibility in HOCM patients, both before and after undergoing PTSMA to reduce the LVOT gradient. By revisiting invasive pressure-volume (PV) data from Steendijk et&#x000a0;al,<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> we analyzed LV function in 14 HOCM patients, focusing on Anrep signature parameters, mechanical work/efficiency indices (stroke work [SW], potential energy [PE], and PV area), and diastolic compliance metrics. A <xref rid="fig5" ref-type="fig">Central Illustration</xref> provides a visual overview of the study methodology and key findings.<fig id="fig5"><label>Central Illustration</label><caption><p>Impact of Septal Ablation on the Anrep Effect in Hypertrophic Obstructive Cardiomyopathy</p><p>This figure illustrates the hemodynamic changes in HOCM preseptal and postseptal ablation. The left panel shows preablation with obstructed septum and elevated afterload, leading to activation of the Anrep effect (increased contractility and prolonged systolic period). The right panel shows postseptal ablation, where obstruction is reduced, reversing the Anrep effect, improving mechanical efficiency, and lowering cardiac workload. The pressure-volume loop graph compares preablation (in blue) and postablation (in red) hemodynamics, emphasizing reductions in afterload, contractility, and systolic duration. Abbreviation as in <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>.</p></caption><graphic xlink:href="gr5"/></fig></p><sec id="sec1"><title>Methods</title><sec id="sec1.1"><title>Patient population</title><p id="p0025">This retrospective study, based on data from Steendijk et&#x000a0;al,<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> was conducted at the Thoraxcenter at Erasmus Medical Center in Rotterdam, the Netherlands. The study was approved by the Institutional Review Board of Erasmus Medical Center, and all patients provided written informed consent before participation. Seventeen individuals diagnosed with HOCM were initially enrolled and underwent PTSMA after receiving optimal medical treatment for over 6&#x000a0;months. Diagnosis of HOCM was confirmed through clinical, echocardiographic, and angiocardiographic assessments. Eligibility criteria included patients in NYHA functional class II-IV with&#x000a0;significant LVOTO, characterized by a systolic gradient over 50&#x000a0;mm&#x000a0;Hg at rest or during provocation, septal thickness above 15&#x000a0;mm, SAM of the mitral valve, and mild or less mitral regurgitation. Two patients exhibited increased LVOT gradients exceeding 50&#x000a0;mm&#x000a0;Hg only during exercise or the Valsalva maneuver. The cohort included 2 cases of familial HOCM and 4 with presumed hypertension. Baseline clinical and hemodynamic characteristics are presented in <xref rid="tbl1" ref-type="table">Tables&#x000a0;1</xref> and <xref rid="tbl2" ref-type="table">2</xref>.<table-wrap position="float" id="tbl1"><label>Table&#x000a0;1</label><caption><p>Baseline Characteristics of HOCM Patients (N&#x000a0;=&#x000a0;17)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>Median [Q1 -Q3] or n (%)</th></tr></thead><tbody><tr><td colspan="2">Demographics</td></tr><tr><td>&#x000a0;Age, y</td><td align="center">60 (52-72)</td></tr><tr><td>&#x000a0;Male</td><td align="center">11 (64%)</td></tr><tr><td>&#x000a0;Female</td><td align="center">6 (36%)</td></tr><tr><td colspan="2">Symptoms</td></tr><tr><td>&#x000a0;Angina</td><td align="center">6 (35%)</td></tr><tr><td>&#x000a0;Dyspnea</td><td align="center">8 (47%)</td></tr><tr><td>&#x000a0;Syncope</td><td align="center">3 (18%)</td></tr><tr><td colspan="2">Medications</td></tr><tr><td>&#x000a0;&#x003b2;-blockers</td><td align="center">9 (53%)</td></tr><tr><td>&#x000a0;Calcium channel antagonists</td><td align="center">10 (59%)</td></tr><tr><td>&#x000a0;Diuretics</td><td align="center">6 (35%)</td></tr><tr><td colspan="2">NYHA functional class</td></tr><tr><td>&#x000a0;IV</td><td align="center">0 (0%)</td></tr><tr><td>&#x000a0;III</td><td align="center">8 (47%)</td></tr><tr><td>&#x000a0;II</td><td align="center">9 (53%)</td></tr><tr><td>Echocardiographic parameters</td><td/></tr><tr><td>&#x000a0;LVOT gradient (mm&#x000a0;Hg)</td><td align="center">80 (20-100)</td></tr><tr><td>&#x000a0;Maximal LV wall thickness (mm)</td><td align="center">21.5 (18.5-25)</td></tr><tr><td>&#x000a0;Ejection fraction (%)</td><td align="center">77 (71-86)</td></tr><tr><td colspan="2">SAM severity</td></tr><tr><td>&#x000a0;Severe</td><td align="center">10 (58.8%)</td></tr><tr><td>&#x000a0;Moderate</td><td align="center">3 (17.6%)</td></tr><tr><td>&#x000a0;Mild</td><td align="center">3 (17.6%)</td></tr><tr><td>&#x000a0;Nonexisting</td><td align="center">1 (6%)</td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>Values are median (IQR) or n (%). SAM severity is categorized as follows: mild (brief SAM without septal contact), moderate (SAM with septal contact lasting less than one-third of the systolic phase), and severe (SAM with septal contact exceeding one-third of systole). Adapted from <italic>Heart</italic>, Steendijk P et&#x000a0;al, Volume 94, Issue 10, Pages 1,318 to 1,322, Copyright &#x000a9;2008, with permission from BMJ Publishing Group Ltd.</p></fn><fn id="tspara0020"><p>HOCM&#x000a0;=&#x000a0;hypertrophic obstructive cardiomyopathy; LV&#x000a0;=&#x000a0;left ventricular; LVOT gradient&#x000a0;=&#x000a0;left ventricular outflow tract gradient; SAM&#x000a0;=&#x000a0;systolic anterior motion of the mitral valve; NYHA&#x000a0;=&#x000a0;New York Heart Association.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl2"><label>Table&#x000a0;2</label><caption><p>Changes in Key Hemodynamic Parameters in HOCM Patients Pre- and Post-PTSMA (N&#x000a0;=&#x000a0;14)</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Pre-PTSMA</th><th>Post-PTSMA</th><th><italic>P</italic> Value</th></tr></thead><tbody><tr><td colspan="4">General</td></tr><tr><td>&#x000a0;Heart rate (beats/min)</td><td align="center">65 (59-79)</td><td align="center">67 (59-79)</td><td align="center">0.82</td></tr><tr><td>&#x000a0;Ejection fraction (%)</td><td align="center">69 (62-74)</td><td align="center">59 (52-66)</td><td align="center">0.0007</td></tr><tr><td>&#x000a0;Stroke volume (mL)</td><td align="center">60 (51-90)</td><td align="center">66 (49-81)</td><td align="center">0.37</td></tr><tr><td colspan="4">Afterload</td></tr><tr><td>&#x000a0;LVOT gradient (mm&#x000a0;Hg)</td><td align="center">80 (20-100)</td><td align="center">0 (0-30)</td><td align="center">0.001</td></tr><tr><td>&#x000a0;ESP (mm&#x000a0;Hg)</td><td align="center">180 (168-210)</td><td align="center">138 (121-160)</td><td align="center">0.0001</td></tr><tr><td>&#x000a0;Ea (mm&#x000a0;Hg/mL)</td><td align="center">2.5 (1.9-3.0)</td><td align="center">1.9 (1.4-2.4)</td><td align="center">0.002</td></tr><tr><td colspan="4">Contractility</td></tr><tr><td>&#x000a0;Ees (mm&#x000a0;Hg/mL)</td><td align="center">2.0 (1.7-3.2)</td><td align="center">1.5 (0.9-2.2)</td><td align="center">0.0001</td></tr><tr><td>&#x000a0;dP/dt<sub>max</sub> (mm&#x000a0;Hg/s)</td><td align="center">1,775 (1,670-1,882)</td><td align="center">1,560 (1,309-1,816)</td><td align="center">0.017</td></tr><tr><td>&#x000a0;ESV<sub>150</sub> (mL)</td><td align="center">24 (16-35)</td><td align="center">47 (40-72)</td><td align="center">0.0006</td></tr><tr><td>&#x000a0;P<sub>iso</sub> (mm&#x000a0;Hg)</td><td align="center">268 (231-304)</td><td align="center">217 (191-233)</td><td align="center">0.0007</td></tr><tr><td colspan="4">Systolic duration</td></tr><tr><td>&#x000a0;dTes (ms)</td><td align="center">371 (363-393)</td><td align="center">327 (307-367)</td><td align="center">0.002</td></tr><tr><td>&#x000a0;dTes<sub>c</sub> (ms)</td><td align="center">402 (363-412)</td><td align="center">346 (325-367)</td><td align="center">0.002</td></tr><tr><td>&#x000a0;dTdPdt (ms)</td><td align="center">362 (331-396)</td><td align="center">344 (307-372)</td><td align="center">0.02</td></tr><tr><td>&#x000a0;dTdPdt<sub>c</sub> (ms)</td><td align="center">381 (343-404)</td><td align="center">340 (321-395)</td><td align="center">0.02</td></tr><tr><td colspan="4">Energy and efficiency</td></tr><tr><td>&#x000a0;SW (mm&#x000a0;Hg&#x000b7;mL)</td><td align="center">8,161 (6,892-11,462)</td><td align="center">7,495 (5,643-10,374)</td><td align="center">0.004</td></tr><tr><td>&#x000a0;PE (mm&#x000a0;Hg&#x000b7;mL)</td><td align="center">7,837 (4,990-18,925)</td><td align="center">4,915 (3,637-8,621)</td><td align="center">0.002</td></tr><tr><td>&#x000a0;PVA (mm&#x000a0;Hg&#x000b7;mL)</td><td align="center">16,135 (12,345-33,075)</td><td align="center">11,742 (10,101-18,996)</td><td align="center">0.0002</td></tr><tr><td>&#x000a0;ME (SW/PVA) (%)</td><td align="center">50 (38-59)</td><td align="center">59 (55-63)</td><td align="center">0.03</td></tr><tr><td colspan="4">Diastolic function</td></tr><tr><td>&#x000a0;EDP (mm&#x000a0;Hg)</td><td align="center">25 (18-27)</td><td align="center">19 (13-26)</td><td align="center">0.07</td></tr><tr><td>&#x000a0;EDV (mL)</td><td align="center">96 (76-137)</td><td align="center">109 (96-140)</td><td align="center">0.01</td></tr><tr><td>&#x000a0;EDV<sub>15</sub> (mL)</td><td align="center">73 (60-116)</td><td align="center">112 (76-135)</td><td align="center">0.002</td></tr><tr><td>&#x000a0;dP/dt<sub>min</sub> (mm&#x000a0;Hg/s)</td><td align="center">&#x02212;1,646 (&#x02212;1,891 to&#x000a0;&#x02212;1,448)</td><td align="center">&#x02212;1,321 (&#x02212;1,549 to&#x000a0;&#x02212;1,167)</td><td align="center">0.02</td></tr></tbody></table><table-wrap-foot><fn id="tspara0030"><p>Values are median (IQR). Adapted from <italic>Heart</italic>, Steendijk P et&#x000a0;al, Volume 94, Issue 10, Pages 1,318 to 1,322, Copyright &#x000a9;2008, with permission from BMJ Publishing Group Ltd.</p></fn><fn id="tspara0035"><p>dP/dt<sub>max</sub>&#x000a0;=&#x000a0;maximum rate of pressure rise; dP/dt<sub>min</sub>&#x000a0;=&#x000a0;minimum rate of pressure decrease; dTdPdt&#x000a0;=&#x000a0;time between dP/dt<sub>max</sub> and dP/dt<sub>min</sub>; dTdPdt<sub>c</sub>&#x000a0;=&#x000a0;dTdPdt corrected for heart rate; dTes&#x000a0;=&#x000a0;duration of systole; dTes<sub>c</sub>&#x000a0;=&#x000a0;duration of systole corrected for heart rate; Ea&#x000a0;=&#x000a0;effective arterial elastance; Ees&#x000a0;=&#x000a0;end-systolic elastance; EDP&#x000a0;=&#x000a0;left ventricular end-diastolic pressure; EDV&#x000a0;=&#x000a0;end-diastolic volume; EDV<sub>15</sub>&#x000a0;=&#x000a0;left ventricular end-diastolic volume at a pressure of 15&#x000a0;mm&#x000a0;Hg; ESP&#x000a0;=&#x000a0;left ventricular end-systolic pressure; ESV<sub>150</sub>&#x000a0;=&#x000a0;end-systolic volume at 150&#x000a0;mm&#x000a0;Hg; ME&#x000a0;=&#x000a0;mechanical efficiency (SW/PVA ratio); PE&#x000a0;=&#x000a0;potential energy; P<sub>iso</sub>&#x000a0;=&#x000a0;isometric pressure maximum; PTSMA&#x000a0;=&#x000a0;percutaneous transluminal septal myocardial ablation; PVA&#x000a0;=&#x000a0;pressure-volume area; SW&#x000a0;=&#x000a0;stroke work; other abbreviations as in <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec1.2"><title>Septal ablation procedure</title><p id="p0030">The PTSMA procedure was performed uniformly across all participants as described in Steendijk et&#x000a0;al.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Initially, a 6F transfemoral pacemaker was placed in the right ventricle for all patients. Baseline hemodynamic data, including LVOT gradient assessments, were recorded at rest. The procedure involved using a 6F percutaneous coronary angioplasty guiding catheter for selective vessel probing, guided by intraprocedural myocardial contrast transthoracic echocardiography. After confirming appropriate vessel closure by balloon inflation, 1 to 2&#x000a0;mL of alcohol was injected slowly through the balloon catheter lumen under continuous transthoracic echocardiography imaging to reduce the LVOT gradient. Care was taken to prevent alcohol leakage into major coronary branches. Hemodynamic measurements were repeated within 10&#x000a0;minutes postprocedure, and pacemaker leads were monitored for at least 48&#x000a0;hours to ensure patient safety.</p></sec><sec id="sec1.3"><title>Hemodynamics and LV function</title><p id="p0035">LV function in the initially enrolled 17 HOCM patients undergoing PTSMA was assessed using PV loops obtained via 7F combined pressure-conductance catheters (CD Leycom) connected to a Cardiac Function Lab (CFL-512, CD Leycom). Steady-state loops, recorded pre- and acutely post-PTSMA (&#x0003c;10&#x000a0;min), were calibrated to echocardiographically determined end-diastolic (EDV) and end-systolic (ESV) volumes, as well as stroke volume.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> For an illustrative representation of a typical PV loop, illustrating key concepts of LV mechanics, refer to <xref rid="fig1" ref-type="fig">Figure&#x000a0;1A</xref>. The ESPVR was determined using a single-beat estimation, characterized by its slope (Ees) and volume axis intersection (V<sub>0</sub>), with contractility inferred from these attributes.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> The LV end-systolic volume at a predefined LVESP of 150&#x000a0;mm&#x000a0;Hg (ESV<sub>150</sub>, denoted by the black horizontal dashed line) was calculated by integrating the ESPVR slope and volume intercept (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1B</xref>). Diastolic function was assessed by calculating LV diastolic capacity (LVEDV<sub>15</sub>, marked by the black horizontal dashed line) as the EDV at a predefined LV end-diastolic pressure of 15&#x000a0;mm&#x000a0;Hg (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1B</xref>). This was calculated using a single-beat end-diastolic PV relationship (EDPVR) with an exponential fit using the equation LV end-diastolic pressure&#x000a0;=&#x000a0;k&#x000d7;e<sup>(&#x003b2;&#x000d7;LVEDV)</sup>, where &#x003b2; is the chamber stiffness coefficient and k is the fitting constant. LV diastolic capacity was then calculated as: LVEDV<sub>15</sub>&#x000a0;=&#x000a0;Ln (15)/(k&#x000d7;&#x003b2;), according to Ten Brinke et&#x000a0;al.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> The time-varying elastance approach was adopted to examine the temporal evolution of LV contractility. Instantaneous elastance, E(t), was calculated for each PV loop point by connecting V<sub>0</sub> to that specific PV point: E(t)&#x000a0;=&#x000a0;P(t)/[V(t)-V<sub>0</sub>]. Elastance-time curves were plotted from each heartbeat, with peak values denoted as Ees, defining end-systole (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>). The dTes, the time interval from end-diastole (marked by the R-wave of the QRS complex) to end-systole, represents the entire systolic phase, including both isovolumic contraction and ejection phases (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>). This interval is less load-dependent than previously used indices such as systolic ejection time.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> Additionally, the time between dP/dt<sub>max</sub> and dP/dt<sub>min</sub> (dTdPdt) was assessed as another method to evaluate the systolic period (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>). In patients with HOCM, the pressure rise and decay often exhibit a biphasic pattern. When the dP/dt curve showed biphasic behavior, the interval between the first positive peak of dP/dt<sub>max</sub> and the second negative peak of dP/dt<sub>min</sub> was measured. To account for heart rate influence on systolic duration, the Fridericia formula for QT interval correction (QT<sub>c</sub>&#x000a0;=&#x000a0;QT/[RR<sup>1/3</sup>]) was applied to all data, standardizing systolic duration to a heart rate of 60&#x000a0;bpm.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> This provided heart rate-corrected durations for both dTes and dTdPdt, termed dTes<sub>c</sub> and dTdPdt<sub>c</sub>, respectively. Indicators of contractility included Ees, ESV<sub>150</sub>, and dP/dt<sub>max</sub>. LVESP and effective arterial elastance (Ea) were used as indicators of the afterload. LV SW is the area surrounded by the LV PV loop, while PE is the triangle bordered by the ESPVR, the volume axis, and the LV PV loop (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1A</xref>). Total PV area (PVA&#x000a0;=&#x000a0;PE&#x000a0;+&#x000a0;SW) correlates well with myocardial oxygen consumption,<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> and LV mechanical efficiency was defined by SW/PVA.<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Hemodynamic Responses in Hypertrophic Obstructive Cardiomyopathy Preseptal/Postseptal Ablation</p><p>(A) Typical pressure-volume loop (black) outlines key indices of LV function such as ESPVR (dashed red-line), EDPVR (dashed blue-line), and Ea (dashed green-line), along with SV, SW, PE, and total PV area (PVA&#x000a0;=&#x000a0;PE&#x000a0;+&#x000a0;SW). (B) Representative pressure-volume loops from a HOCM patient preseptal (blue) and postseptal ablation (red), with a postprocedure rightward shift in ESPVR and increased ESV<sub>15</sub> (black dashed line and solid red circle), indicating reduced contractility, and a rightward EDPVR shift with higher EDV<sub>15</sub> (black dashed line and red diamond), denoting augmented diastolic capacity. Theoretical isovolumic pressure-volume loops (blue- and red-dotted lines) highlight the Anrep's role in offsetting increased afterload. Symbols represent measurement points: open circles for ESV and ESP, solid circles for ESV<sub>150</sub>, diamonds for EDV<sub>15</sub>, and squares for P<sub>iso</sub>. Black dashed lines denote pressures of 150 and 15&#x000a0;mm&#x000a0;Hg, while vertical dashes visualize theoretical isovolumic contractions. EDPVR, End-Diastolic Pressure-volume Relationship; EDV<sub>15</sub>&#x000a0;=&#x000a0;left ventricular end-diastolic volume at a pressure of 15&#x000a0;mm&#x000a0;Hg; ESP&#x000a0;=&#x000a0;left ventricular end-systolic pressure; ESPVR = end-systolic pressure-volume relationship; ESV<sub>150</sub>&#x000a0;=&#x000a0;end-systolic volume 150&#x000a0;mm&#x000a0;Hg; HOCM&#x000a0;=&#x000a0;hypertrophic obstructive cardiomyopathy; LV&#x000a0;=&#x000a0;left ventricular; PE&#x000a0;=&#x000a0;potential energy; P<sub>iso</sub>&#x000a0;=&#x000a0;isometric pressure maximum; PV&#x000a0;=&#x000a0;pressure-volume; PVA&#x000a0;=&#x000a0;pressure-volume area; SW&#x000a0;=&#x000a0;stroke work.</p></caption><graphic xlink:href="gr1"/></fig><fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>Hemodynamic Analysis in Hypertrophic Obstructive Cardiomyopathy Preseptal/Postseptal Ablation</p><p>Shown are preseptal (blue) and postseptal ablation (red) traces of volume-time, left ventricle (LV) and aortic (Ao) pressure-time, dP/dt, elastance-time, and electrocardiograms (ECG). Synchronization of preseptal and postseptal ablation traces at the onset of the QRS complex in the ECG is marked by the dashed black line at t&#x000a0;=&#x000a0;0 (the second beat of both examples). The figure demonstrates, postseptal ablation, reductions in dP/dt<sub>min</sub> and dP/dt<sub>max</sub>, a decrease in end-systolic elastance (Ees, depicted with dashed vertical red lines), and a shortened time to reach end-systolic elastance (dTes, depicted with horizontal dotted black lines). The aortic and LV pressure traces illustrate the removal of the LV-aortic pressure gradient through septal ablation, highlighting the procedural success in alleviating hemodynamic obstruction. Adapted from <italic>Heart</italic>, Steendijk P et&#x000a0;al, Volume 94, Issue 10, Pages 1,318 to 1,322, Copyright &#x000a9;2008, with permission from BMJ Publishing Group Ltd. dP/dt<sub>max</sub>&#x000a0;=&#x000a0;maximum rate of pressure rise; dP/dt<sub>min</sub>&#x000a0;=&#x000a0;minimum rate of pressure decrease.</p></caption><graphic xlink:href="gr2"/></fig></p></sec><sec id="sec1.4"><title>Statistics</title><p id="p0040">Given the small sample size and the assumption of non-normal distribution, all continuous variables were analyzed using the nonparametric Wilcoxon signed rank test. Continuous variables are reported as median with first (Q1) and third (Q3) quartiles. A <italic>P</italic> value&#x000a0;&#x0003c;0.05 was considered statistical significance. Analyses were performed using GraphPad Prism 8.1.2.</p></sec></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Patient clinical characteristics</title><p id="p0045">In this study, 17 patients with HOCM underwent PTSMA to relieve LVOTO. Baseline clinical characteristics are presented in <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>. The cohort had a median age of 60 (52-72) years, with 6 patients reporting angina, 3 syncope, and 8 dyspnea. Despite optimal medical therapy (&#x003b2;-blockers, calcium channel blockers, diuretics), 8 patients were NYHA functional class III and 9 patients were class II (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>). Preprocedural echocardiographic assessments confirmed significant LVOTO in all patients: resting gradient 80 (20-100) mm&#x000a0;Hg, septal thickness 21.5 (18.5-25) mm, SAM classified as severe or moderate in 13 of 17 cases, and mild mitral regurgitation in all cases (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>). Postprocedure, LVOT gradient decreased to 0 (0-30) mm&#x000a0;Hg (from 80 [IQR: 20-100], <italic>P</italic>&#x000a0;=&#x000a0;0.001), SAM resolved or was reduced to mild, and mitral regurgitation was no longer detectable.</p></sec><sec id="sec2.2"><title>Hemodynamic changes in HOCM: activation and reversal of the Anrep effect</title><p id="p0050">LV function was assessed by invasive PV catheterization in all 17 HOCM patients. However, 3 individuals were excluded from the final analysis: 2 due to insufficient afterload reduction post-PTSMA at rest (a key criterion for assessing the procedure's efficacy) and elevated LVOT gradients appearing only during exercise or Valsalva maneuvers, and one due to poor PV signal quality. Preprocedure and postprocedure hemodynamic parameters of the 14 included patients are summarized in <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>. Representative PV loops from a patient pre- (blue) and post-PTSMA (red) are shown in <xref rid="fig1" ref-type="fig">Figure&#x000a0;1B</xref>.</p><p id="p0055">The Anrep Triad&#x02014;comprising elevated afterload (LVESP, Ea), increased contractility (Ees, dP/dt<sub>max</sub>), and prolonged systole (dTes, dTdP/dt)&#x02014;was assessed through invasive comparison of pre- and post-PTSMA hemodynamics. Postprocedure, afterload reduction paralleled the decline in resting LVOT gradient: LVESP decreased from 180 (IQR: 168-210) to 138 (IQR: 121-160) mm&#x000a0;Hg (<italic>P</italic>&#x000a0;=&#x000a0;0.0001), and Ea from 2.5 (IQR: 1.9-3.0) to 1.9 (IQR: 1.4-2.4) mm&#x000a0;Hg/mL (<italic>P</italic>&#x000a0;=&#x000a0;0.002) (<xref rid="fig1" ref-type="fig">Figures&#x000a0;1B</xref>, <xref rid="fig2" ref-type="fig">2</xref>, and <xref rid="fig3" ref-type="fig">3A</xref>, <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). Concomitantly, contractility decreased, evidenced by a rightward shift in the ESPVR (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1B</xref>), a drop in Ees from 2.0 (IQR: 1.7-3.2) to 1.5 (0.9-2.2) mm&#x000a0;Hg/mL (<italic>P</italic>&#x000a0;=&#x000a0;0.0001) (<xref rid="fig2" ref-type="fig">Figures&#x000a0;2</xref> and <xref rid="fig3" ref-type="fig">3B</xref>), and an increase in ESV<sub>150</sub> from 24 (IQR: 16-35) to 47 (IQR: 40-72) mL (<italic>P</italic>&#x000a0;=&#x000a0;0.0006) (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1B</xref>, solid red circle; <xref rid="fig3" ref-type="fig">Figure&#x000a0;3C</xref> and <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). Additionally, dP/dt<sub>max</sub> decreased from 1,775 (IQR: 1,670-1,882) to 1,560 (IQR: 1,309-1,816) (<italic>P</italic>&#x000a0;=&#x000a0;0.017) (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>, <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>). Systolic duration also shortened post-PTSMA: dTes decreased from 371 (IQR: 363-393) to 327 (IQR: 307-367) ms (<italic>P</italic>&#x000a0;=&#x000a0;0.002), and dTdPdt from 362 (IQR: 331-396) to 344 (IQR: 307-372) ms (<italic>P</italic>&#x000a0;=&#x000a0;0.02) (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>, <xref rid="fig3" ref-type="fig">Figure&#x000a0;3D</xref>). Heart rate-corrected durations for both dTes and dTdPdt validated the shortening of the systolic period (dTes<sub>c</sub>: 402 [IQR: 363-412] to 346 [IQR: 325-367] ms, <italic>P</italic>&#x000a0;=&#x000a0;0.002; dTdPdt<sub>c</sub>: 381 [IQR: 343-404] to 340 [IQR: 321-395] ms, <italic>P</italic>&#x000a0;=&#x000a0;0.02) (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>).<fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>Hemodynamic Changes in Hypertrophic Obstructive Cardiomyopathy Preseptal/Postseptal Ablation</p><p>(A) Left ventricular end-systolic pressure (LVESP) shows the pressure within the LV at the end of systole. (B) End-systolic elastance (Ees) represents the stiffness of the LV at the end of systole. (C) End-systolic volume 150&#x000a0;mm&#x000a0;Hg (ESV<sub>150</sub>) quantifies the volume of the&#x000a0;LV when the pressure is at 150&#x000a0;mm&#x000a0;Hg, indicating afterload resistance. (D) The duration of systole (dTes) measures the total time span of the systolic phase of the cardiac cycle. Asterisks (&#x02217;) indicate statistical significance, highlighting the hemodynamic improvement postseptal ablation. Adapted from <italic>Heart</italic>, Steendijk P et&#x000a0;al, Volume 94, Issue 10, Pages 1,318 to 1,322, Copyright &#x000a9;2008, with permission from BMJ Publishing Group Ltd.</p></caption><graphic xlink:href="gr3"/></fig></p><p id="p0060">Collectively, these changes confirm that the Anrep mechanism, typically transient in healthy hearts, becomes chronically activated in HOCM (eg, sustained over months to years) due to continuous high afterload from LVOTO. This sustained activation is shown by persistently elevated baseline parameters (eg, LVESP, Ea, Ees, dP/dt<sub>max</sub>, dTes) prior to PTSMA. Notably, LVOTO relief reversed this chronic activation of the Anrep effect.</p></sec><sec id="sec2.3"><title>Energetic and functional consequences of Anrep reversal</title><p id="p0065">Anrep activation in HOCM, while a compensatory response to maintain stroke volume under high afterload, comes at a high energetic cost. Preprocedure, HOCM patients exhibited an elevated mechanical workload, which significantly decreased following Anrep effect reversal postprocedure. Post-PTSMA, myocardial SW declined from 8,161 (IQR: 6,892-11,462) to 7,495 (IQR: 5,643-10,374) mm&#x000a0;Hg&#x000b7;mL (<italic>P</italic>&#x000a0;=&#x000a0;0.004), PE from 7,837 (4,990-18,925) to 4,915 (IQR: 3,637-8,621) mm&#x000a0;Hg&#x000b7;mL (<italic>P</italic>&#x000a0;=&#x000a0;0.002), and total PVA from 16,135 (IQR: 12,345-33,075) to 11,742 (IQR: 10,101-18,996) mm&#x000a0;Hg&#x000b7;mL (<italic>P</italic>&#x000a0;=&#x000a0;0.0002) (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). This&#x000a0;reduction in workload was paralleled by an improvement in mechanical efficiency, reflected by a rise in SW/PVA from 50 (IQR: 38-59) to 59% (IQR: 55%-63%) (<italic>P</italic>&#x000a0;=&#x000a0;0.03) (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). Although ejection fraction decreased postprocedure (69% [IQR: 62%-74%] to 59% [IQR: 52%-66%], <italic>P</italic>&#x000a0;=&#x000a0;0.0007), stroke volume remained unaffected (60 [IQR: 51-90] mL vs 66 [IQR: 49-81] mL, <italic>P</italic>&#x000a0;=&#x000a0;0.37) (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). Additionally, -dP/dt<sub>min</sub> decreased post-PTSMA from&#x000a0;&#x02212;1,646 (IQR: &#x02212;1,891 to&#x000a0;&#x02212;1,448) mm Hg/s to&#x000a0;&#x02212;1,321 (IQR: &#x02212;1,549 to&#x000a0;&#x02212;1,167) mm&#x000a0;Hg/s (<italic>P</italic>&#x000a0;=&#x000a0;0.02) (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>, <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>), suggesting a slight prolongation in myocardial relaxation. However, this was accompanied by a rightward shift of the EDPVR and an increase in EDV<sub>15</sub> from 73 (IQR: 60-116) mL to 112 (IQR: 76-135) mL (<italic>P</italic>&#x000a0;=&#x000a0;0.002) (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1B</xref>, solid red diamond; <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>), and a higher EDV at a trending lower EDP (25&#x000a0;[IQR: 18-27] mm Hg to 19 [IQR: 13-26] mm&#x000a0;Hg; <italic>P</italic>&#x000a0;=&#x000a0;0.07), indicating improved diastolic compliance. These findings support enhanced ventricular filling and attenuation of diastolic dysfunction following septal reduction therapy.</p></sec></sec><sec id="sec3"><title>Discussion</title><p id="p0070">This study advances prior evidence of chronic Anrep effect activation in HOCM, previously detected via noninvasive echocardiography.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> We applied invasive pressure-volumetry analysis, recognized as the definitive standard for evaluating cardiac function through direct measurements of ventricular pressures and volumes. This approach overcomes the geometric assumptions inherent in echocardiographic methods, providing greater precision in assessing cardiac mechanics and energy dynamics. Using a new cohort of 14 HOCM patients, we confirmed the sustained activation of the Anrep effect and documented its rapid reversal following PTSMA. This finding supports the effect&#x02019;s sensitivity to afterload reduction and its role as a dynamic compensatory mechanism. Additionally, we introduce the concept of the <italic>Anrep Triad</italic>, a novel hemodynamic signature comprising 3 core features: elevated afterload (increased LVESP and Ea), enhanced contractility (leftward shift of ESPVR, steeper Ees slope, higher dP/dt<sub>max</sub>), and a prolonged systolic phase (dTes, dTdPdt) (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>, <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). Key findings are summarized in <xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>.<fig id="fig4"><label>Figure&#x000a0;4</label><caption><p>The Anrep Effect and Its Reversal in Hypertrophic Obstructive Cardiomyopathy Postseptal Ablation</p><p>This conceptual diagram synthesizes the study's main findings, showcasing the Anrep effect&#x02019;s role in maintaining cardiac function under increased afterload (left) and its reversal postseptal ablation (right) in HOCM. Key hemodynamic measurements included left ventricular (LV) end-systolic pressure (LVESP) and effective arterial elastance (Ea) as afterload indicators, and contractility indices such as end-systolic elastance (Ees), the maximum rate of LV pressure rise (dP/dt<sub>max</sub>), and the duration of systole (dTes). Stroke work (SW), potential energy (PE), and total pressure-volume area (PVA) quantified mechanical work and efficiency (SW/PVA). Postablation, LVESP, Ea, Ees, dP/dt<sub>max</sub>, dTes, SW, PE, and PVA were all significantly reduced, indicating decreases in afterload, contractility, and mechanical work, leading to improved cardiac efficiency and function. Symbols: &#x02191; Increase, &#x02193; Decrease. Abbreviations as in <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>.</p></caption><graphic xlink:href="gr4"/></fig></p><p id="p0075">Activation of the Anrep effect in HOCM imposes a heavy mechanical workload (higher SW, PE, and PVA) and leads to a reduction in LV capacity, signaling diminished mechanical efficiency and high energy consumption. Moreover, the Anrep effect contributes to a deterioration in LV diastolic filling, as evidenced by the leftward shift of the EDPVR and a lower EDV<sub>15</sub> (see the blue PV loop in <xref rid="fig1" ref-type="fig">Figure&#x000a0;1B</xref> and <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). These findings support the notion that, while the Anrep effect is an adaptive response to increased afterload, it is energetically costly and imposes significant mechanical stress on the myocardium. Under physiological conditions, the transient, energy-intensive nature of the Anrep effect is balanced by efficient energy delivery, optimal coronary flow reserve, ample oxygen supply, and well-functioning energy recycling systems. However, in HOCM, this balance becomes progressively disturbed by changes in mitochondrial energy substrates<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> and mitochondrial dysfunction,<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> limited myocardial perfusion,<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> and reduced coronary flow reserve.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> These changes are compounded by a decrease in phosphocreatine/ATP ratios at rest,<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> which worsens under physical stress,<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> and decreased cardiac work efficiency, further exacerbated by LVOTO.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> These observations align with the chronic activation of the Anrep effect we document, underscoring that while the Anrep effect augments LV contractility in response to high afterload, its prolonged, energy-intensive nature <italic>exhausts</italic> energy reserves and reduces mechanical work efficiency if not supported by adequate systemic metabolic health.</p><sec id="sec3.1"><title>Reversing the Anrep effect: impact of PTSMA</title><p id="p0080">PTSMA offers an effective intervention to reduce LVOTO and alleviate the mechanical and energetic demands imposed by the Anrep effect. This is evidenced by significant reductions in afterload (LVESP, Ea) and key contractility parameters (dTes and dTdPdt, Ees, and dP/dt<sub>max</sub>), alongside decreases in cardiac workload (SW, PE, and PVA), ultimately leading to improved mechanical efficiency (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). Importantly, the reversal of the Anrep Triad occurs independent of confounding variations in catecholamines, heart rate, the Gregg effect, preload adjustments, or myocardial damage. A decrease in catecholamine levels, for instance, would be expected to reduce contractility and prolong systole,<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> a trend that was not observed in our data. Similarly, the unchanged heart rate before and after PTSMA rules out any influence of the Bowditch effect (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). While microvascular dysfunction<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> and reduced coronary flow reserve<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> are known to improve partially with LVOTO relief,<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> their impact on contractility in this context (the Gregg effect) is likely minimal, as coronary perfusion remains within the autoregulatory range and is not expected to significantly influence contractility in blood-perfused tissues.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> But any potential improvement in contractility from enhanced coronary perfusion would likely work to offset, rather than fully counteract, the decrease in contractility observed postprocedure. Additionally, the potential role of the slow force response, marked by delayed contractility increases after an elevation in EDV post-PTSMA, would only serve to lessen the reduction in contractility following Anrep effect reversal.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> An increase in EDV post-PTSMA could likewise recruit the Frank-Starling mechanism, preserving stroke volume and offsetting any decrease in contractility (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1B</xref>). Given that our hemodynamic measurements were taken within 10&#x000a0;minutes post-PTSMA, before inflammatory responses could peak (typically 3&#x000a0;hours postinjury),<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> it is unlikely that negative inotropic influence resulting from inflammatory responses impacted our findings. Even in the presence of localized myocardial injury, the targeted nature of PTSMA, which induces scar formation specifically in the septal region, helps limit the extent of functional impairment.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> Thus, PTSMA is unlikely to impair global LV function.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> Moreover, continued administration of &#x003b2;-blockers, calcium channel antagonists, and diuretics post-PTSMA ensures uniform accounting for any confounding pharmacological effects, allowing for a clearer understanding of the procedure's impact on Anrep-related hemodynamics. Collectively, these factors strongly suggest that the observed improvements post-PTSMA are directly attributable to afterload reduction and the reversal of the Anrep effect, independent of external confounding influences such as catecholamines, preload variations, tissue inflammation, or pharmacological interventions.</p></sec><sec id="sec3.2"><title>Molecular mechanisms responsible for the Anrep effect in HOCM</title><p id="p0085">Understanding the molecular basis of the Anrep Triad is key to explaining its high mechanical and energetic requirements and the efficacy of interventions like PTSMA in improving mechanical efficiency in HOCM. The Anrep effect allows the heart to sustain contractility under elevated afterload by recruiting myosin motors from a normally inactive reserve within cardiomyocytes.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> Approximately 55% of sarcomeric myosin heads are held in this energy-conserving inactive state (reserve pool), minimizing ATP consumption.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> When afterload increases, a greater proportion of these myosin heads transition from inactivity to activation, making them available for actin binding and force generation; this transition correlates with the activation of the Anrep effect. This process may involve a calcium feedback mechanism that responds to afterload, dynamically adjusting calcium availability to sustain sarcomere activation and force production under elevated wall stress.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref></p><p id="p0090">In HOCM, the Anrep effect, normally transient and adaptive, undergoes chronic overactivation. The persistent elevation in afterload caused by LVOTO disrupts the equilibrium between inactive and active myosin states, leading to excessive myosin recruitment and sustained hypercontractility.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> The activation of the Anrep effect in HOCM is characterized by:<list list-type="simple" id="olist0010"><list-item id="o0010"><label>1.</label><p id="p0095">Afterload-sensitive (myosin recruitment) phase: Prolonged wall stress from sustained afterload elevation due to LVOTO continuously activates dormant myosin heads from the reserve pool, while prolonging the duration of myosin-actin (cross-bridge) interactions.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> This process amplifies LV contractility, extends the duration of systole, and raises energy demand, hallmarks of Anrep effect activation observed in obstructive HCM (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>).</p></list-item><list-item id="o0015"><label>2.</label><p id="p0100">Pathogenic-dependent (myosin recruitment) phase: An estimated 20% of myosin heads are recruited from the inactive reserve pool due to sarcomeric pathogenic variants, post-translational modifications (eg, phosphorylation of myosin-binding protein C or myosin light chain), or shifts in myocardial energetics, particularly a decrease in the ATP/ADP ratio.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> These molecular events <italic>compound</italic> the activation of the Anrep effect by destabilizing myosin&#x02019;s resting configuration, causing excessive myosin-actin engagement.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> This establishes a &#x0201c;baseline&#x0201d; level of hypercontractility, already observed in nonobstructive HCM.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="bib31" ref-type="bibr"><sup>31</sup></xref></p></list-item></list></p><p id="p0105">The combined activation of these processes explains why the Anrep effect is both energetically costly and reversible in HOCM. An increased number of active myosin motors raises the energetic cost of contraction,<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> depletes myocardial energy reserves,<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> and elevates SW, PE, and PVA (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). Post-PTSMA, these (energy-consuming) metrics decrease as afterload is reduced, allowing myosin heads to return to their dormant (energy-efficient) state, reducing contractility, shortening systole, and improving mechanical efficiency (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). The observed improvements in diastolic compliance, indicated by an increased EDV at a trending lower EDP (<italic>P</italic>&#x000a0;=&#x000a0;0.07) (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>), support this deactivation of myosin, reducing myocardial stiffness and enhancing ventricular filling. This allows the heart to recruit the Frank-Starling reserve, maintaining stroke volume <italic>despite</italic> the limited capacity of preload to augment contraction in HCM (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1B</xref>, <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>).<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> Future research should investigate the molecular dynamics of the Anrep Triad, particularly focusing on noninvasive therapies targeting this energy-consuming process. Preclinical and clinical studies on myosin inhibitors, such as mavacamten, support this concept by demonstrating their ability to lower hypercontractility, reduce cellular energy consumption,<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> and improve LVOT gradients and diastolic function.<xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref>, <xref rid="bib38" ref-type="bibr">38</xref></p></sec><sec id="sec3.3"><title>Anrep mismatch: reserve depletion and the progression to end-stage HCM</title><p id="p0110">In HCM, ejection fraction is typically normal or hyperdynamic (&#x0003e;70%), even before the onset of hypertrophy.<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> However, 5% to 15% of patients progress to LV hypokinesia, where ejection fraction falls below 40%. These patients exhibit ventricular dilation, regression of hypertrophy, ischemia, microvascular dysfunction, and diminished coronary reserve.<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> This advanced stage, known as dilated-hypokinetic or end-stage HCM, is often accompanied by severe pulmonary hypertension in up to 80% of cases.<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> When aggravated by LVOTO, afterload increases further, exacerbating heart failure risk.<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> The severity of symptoms and systolic dysfunction in this stage correlates with a reduction in phosphocreatine/ATP ratios, indicating a causal relationship between high mechanical work, ventricular dilation, and energy depletion.<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> In HCM, high mechanical work and energy insufficiency, rather than microvascular impairment, ischemia, hypertrophy, or fibrosis, are antecedents to the progression of disease.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="bib39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> We suspect that, if left untreated, prolonged exposure to high afterload (LVOTO, hypertension), coupled with excessive drainage of myocardial energy reserves,<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> leads to exhaustion of the Anrep reserve, resulting in LV hypokinesia and the transition to end-stage HCM. This condition, where the heart can no longer maintain stroke volume due to inadequate contractility, aligns with John Ross' concept of &#x0201c;afterload mismatch,&#x0201d; described in the late 1970s.<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> We extend this idea, introducing the term <italic>Anrep mismatch</italic>, which denotes the depletion of the Anrep reserve or its failure to compensate for long-term high mechanical demands. This mismatch signifies the peak of chronic high afterload, energy exhaustion, and declining LV contractility.</p><p id="p0115">At the cellular level, severe energy depletion under chronic afterload likely induces a state akin to isometric, <italic>rigor-like</italic> contraction&#x02014;a hypercontracture state.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> In this state, myofibrils contract with minimal shortening and reduced mechanical work, characterized by increased and prolonged contact of myosin heads with actin, which bind strongly and for extended periods in a nonrelaxing (noncycling), rigor-like manner.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> This prevents extensive shortening, reducing ventricular mechanical work and ejection, while the end-stage HCM heart pathologically dilates, attempting to utilize an already compromised preload (Frank-Starling) reserve.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> Our data (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1B</xref>) conceptualize this sequence by illustrating the consequences of reintroducing pre-PTSMA afterload levels (180&#x000a0;mm&#x000a0;Hg) post-PTSMA. The theoretical isovolumic PV loops, represented by blue and red dotted lines, demonstrate the potential state of the heart before and after the procedure (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1B</xref>). If the HCM heart encounters pre-PTSMA levels of afterload post-PTSMA (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1B</xref>, blue open circle), purely isovolumetric contractions could occur (red P<sub>iso</sub>, isometric pressure maximum, &#x0223c;170&#x000a0;mm&#x000a0;Hg). Without sufficient Anrep compensation, the heart would fail to eject any blood, producing no work as the isometric maximum post-PTSMA falls below the pre-PTSMA afterload, preventing aortic valve opening.</p><p id="p0120">Addressing Anrep mismatch requires afterload reduction interventions, such as relieving outflow obstruction in aortic stenosis<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> or HOCM with acute LV hypokinesia.<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> These strategies lead to rapid functional recovery by reducing afterload, improving contractility, and restoring ventricular performance. In summary, persistent high afterload and energy depletion diminish myofibrillar efficiency, shifting the heart toward a low-functioning, hypokinetic state, which is a hallmark of Anrep <italic>mismatch</italic>. This state often coexists with diminished adrenergic activation, limited preload reserve,<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> microvascular impairment, ischemia, or fibrosis, further accelerating LV dysfunction in patients transitioning to <italic>or</italic> already in the end stage of HCM.</p></sec><sec id="sec3.4"><title>Study limitations</title><p id="p0125">The invasive nature of PV catheterization inherently limited our cohort size (N&#x000a0;=&#x000a0;14), reflecting its technical complexity and restricted clinical use in HOCM management. Ethical constraints also precluded the inclusion of a dedicated control group, as invasive catheterization of healthy individuals was not justifiable in this study. Despite these constraints, reference values from healthy individuals with a median age of 65 (62-68) years, as reported by Wachter et&#x000a0;al,<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> provide a useful comparative context. These values, obtained using a similar PV conductance catheter technique, include key Anrep Triad parameters: LVESP (118 [IQR: 111-130] mm&#x000a0;Hg), Ea (1.2 [IQR: 0.8-1.7] mm&#x000a0;Hg/mL), Ees&#x000a0;(1.4 [IQR: 1.26-1.65] mm&#x000a0;Hg/mL), dP/dt<sub>max</sub> (IQR: 1,562 [1,549-1,866] mm&#x000a0;Hg/s), and dTes (354 [IQR: 332-374] ms).<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> A qualitative comparison suggests that our pre-PTSMA HOCM cohort exhibited markedly elevated afterload, increased contractility, and prolonged systole (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). Post-PTSMA, most of our study parameters moved closer to the normative values reported in Wachter et&#x000a0;al,<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> indicating hemodynamic normalization after afterload reduction. Notably, our PV analysis aligns with and extends prior noninvasive observations of the Anrep effect in HOCM,<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> strengthening the evidence for the Anrep Triad&#x02019;s role in this pathology. Finally, the absence of genetic profiling, particularly for sarcomeric pathogenic variants common in HCM, limits exploration of genotype-phenotype correlations influencing Anrep activation. Future studies with larger cohorts, incorporating genetic data and noninvasive PV characterization, are needed to validate these relationships and generalize the Anrep Triad across HOCM subpopulations.</p></sec></sec><sec id="sec4"><title>Conclusions</title><p id="p0130">This study comprehensively examines the chronic activation of the Anrep effect in HOCM, underscoring its significant impact on cardiac function and energy dynamics. Through invasive PV analysis of 14 patients undergoing PTSMA, we identified the distinct Anrep Triad, a hemodynamic signature marked by increased contractility and prolonged systole in response to elevated afterload, which is accompanied by heightened mechanical workload and energy consumption. These findings unify numerous clinical and basic research observations, highlighting that key traits of HOCM, such as hyperdynamic systole, exacerbated diastolic dysfunction, and elevated energy demands, are directly linked to Anrep effect activation. The reversal of this effect following LVOTO removal via septal reduction therapy explains the procedure&#x02019;s success in improving patient outcomes, including symptom relief, enhanced cardiac efficiency, better diastolic function, and improved quality of life. Importantly, the reversal of the Anrep effect post-PTSMA occurs independently of confounding factors like catecholamines, preload variations, inflammation, or pharmacological effects. These results open new avenues for studying the Anrep effect in other cardiac conditions characterized by increased afterload, offering a novel foundation for clinical intervention and future research.<boxed-text id="dtbox1"><label>Perspectives</label><p id="p0135"><bold>COMPETENCY IN MEDICAL KNOWLEDGE 1:</bold> The chronic activation of the Anrep effect in HOCM redefines our understanding of disease progression, shifting the focus from pathogenic variants alone to the role of pathophysiological adaptation driven by persistent afterload due to LVOTO. This study demonstrates that the Anrep effect, typically a transient contractile response to elevated afterload, becomes a prolonged, energy-consuming mechanism in HOCM. Its reversal through septal reduction therapy highlights the critical need to address afterload in order to restore mechanical efficiency. By reducing contractility and mechanical workload while preserving stroke volume, septal ablation relieves the heart's energy-intensive compensatory burden, leading to improved patient outcomes. This direct link between the Anrep effect and cardiac energy dynamics places myocardial energy depletion as a key factor in HOCM pathophysiology, suggesting that therapies targeting this mechanism could attenuate symptoms and slow disease progression.</p><p id="p0140"><bold>COMPETENCY IN MEDICAL KNOWLEDGE 2:</bold> Septal reduction therapy provides a targeted intervention that addresses the chronic effects of afterload on cardiac energy dynamics, restoring mechanical efficiency by reversing the Anrep effect. This study introduces the Anrep Triad&#x02014;elevated afterload, increased contractility, and prolonged systolic duration&#x02014;as a hemodynamic marker that can assist in the clinical evaluation of HOCM. By integrating this triad into routine diagnostic assessments, clinicians can better anticipate disease trajectory, personalize treatment strategies, and ultimately improve patient prognosis and quality of care. The suppression of the Anrep effect posttherapy offers not only symptomatic relief but also long-term improvement in cardiac function.</p><p id="p0145"><bold>TRANSLATIONAL OUTLOOK:</bold> The implications of this study extend beyond HOCM, encouraging further research into the chronic activation of the Anrep effect in other cardiovascular conditions characterized by long-term high afterload, such as aortic stenosis, chronic hypertension, and heart failure with preserved ejection fraction. Investigating the molecular and physiological pathways of the Anrep effect in these settings can lead to the development of novel therapeutic strategies aimed at reducing the heart's mechanical and energetic burden, ultimately resulting in better outcomes for a wide range of patients with elevated afterload.</p></boxed-text></p></sec><sec sec-type="COI-statement" id="coi0010"><title>Funding support and author disclosures</title><p id="p0150">Dr Maack is funded by the <funding-source id="gs1">Deutsche Forschungsgemeinschaft</funding-source> (DFG; SFB-1525/project No. 453989101 and Ma: 2528/8-1); and is an advisory board member for Bristol Myers Squibb, Boehringer Ingelheim, AstraZeneca, Servier, Amgen, Novo Nordisk, Bayer, Novartis, Edwards, and Berlin Chemie. Dr Sequeira is supported by a research fund from <funding-source id="gs2">Bristol Myers Squibb</funding-source> and the <funding-source id="gs3">Deutsche Forschungsgemeinschaft</funding-source> (DFG; No. <award-id award-type="grant" rid="gs3">530849567</award-id>); and has received research funding from Bristol Myers Squibb. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Ommen</surname><given-names>S.R.</given-names></name><name><surname>Mital</surname><given-names>S.</given-names></name><name><surname>Burke</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines</article-title><source>J Am Coll Cardiol</source><volume>76</volume><issue>25</issue><year>2020</year><fpage>e159</fpage><lpage>e240</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2020.08.045</pub-id><pub-id pub-id-type="pmid">33229116</pub-id>
</element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Arbelo</surname><given-names>E.</given-names></name><name><surname>Protonotarios</surname><given-names>A.</given-names></name><name><surname>Gimeno</surname><given-names>J.R.</given-names></name><etal/></person-group><article-title>2023 ESC guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC)</article-title><source>Eur Heart J</source><volume>44</volume><issue>37</issue><year>2023</year><fpage>3503</fpage><lpage>3626</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehad194</pub-id><pub-id pub-id-type="pmid">37622657</pub-id>
</element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Neubauer</surname><given-names>S.</given-names></name><name><surname>Kolm</surname><given-names>P.</given-names></name><name><surname>Ho</surname><given-names>C.Y.</given-names></name><etal/></person-group><article-title>Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry</article-title><source>J&#x000a0;Am Coll Cardiol</source><volume>74</volume><issue>19</issue><year>2019</year><fpage>2333</fpage><lpage>2345</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2019.08.1057</pub-id><pub-id pub-id-type="pmid">31699273</pub-id>
</element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Guigui</surname><given-names>S.A.</given-names></name><name><surname>Torres</surname><given-names>C.</given-names></name><name><surname>Escolar</surname><given-names>E.</given-names></name><name><surname>Mihos</surname><given-names>C.G.</given-names></name></person-group><article-title>Systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: a narrative review</article-title><source>J&#x000a0;Thorac Dis</source><volume>14</volume><issue>6</issue><year>2022</year><fpage>2309</fpage><lpage>2325</lpage><pub-id pub-id-type="pmid">35813751</pub-id>
</element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Steendijk</surname><given-names>P.</given-names></name><name><surname>Meliga</surname><given-names>E.</given-names></name><name><surname>Valgimigli</surname><given-names>M.</given-names></name><name><surname>Ten Cate</surname><given-names>F.J.</given-names></name><name><surname>Serruys</surname><given-names>P.W.</given-names></name></person-group><article-title>Acute effects of alcohol septal ablation on systolic and diastolic left ventricular function in patients with hypertrophic obstructive cardiomyopathy</article-title><source>Heart</source><volume>94</volume><issue>10</issue><year>2008</year><fpage>1318</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1136/hrt.2007.139535</pub-id><pub-id pub-id-type="pmid">18450844</pub-id>
</element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>G&#x000fc;&#x000e7;l&#x000fc;</surname><given-names>A.</given-names></name><name><surname>Knaapen</surname><given-names>P.</given-names></name><name><surname>Harms Hendrik</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Disease stage-dependent changes in cardiac contractile performance and oxygen utilization underlie reduced myocardial efficiency in human inherited hypertrophic cardiomyopathy</article-title><source>Circ Cardiovasc Imag</source><volume>10</volume><issue>5</issue><year>2017</year><object-id pub-id-type="publisher-id">e005604</object-id><pub-id pub-id-type="doi">10.1161/CIRCIMAGING.116.005604</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Cannon</surname><given-names>R.O.</given-names></name><name><surname>McIntosh</surname><given-names>C.L.</given-names></name><name><surname>Schenke</surname><given-names>W.H.</given-names></name><name><surname>Maron</surname><given-names>B.J.</given-names></name><name><surname>Bonow</surname><given-names>R.O.</given-names></name><name><surname>Epstein</surname><given-names>S.E.</given-names></name></person-group><article-title>Effect of surgical reduction of left ventricular outflow obstruction on hemodynamics, coronary flow, and myocardial metabolism in hypertrophic cardiomyopathy</article-title><source>Circulation</source><volume>79</volume><issue>4</issue><year>1989</year><fpage>766</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.79.4.766</pub-id><pub-id pub-id-type="pmid">2924410</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Maron</surname><given-names>B.J.</given-names></name><name><surname>Desai</surname><given-names>M.Y.</given-names></name><name><surname>Nishimura</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>Management of hypertrophic cardiomyopathy: JACC State-of-the-Art Review</article-title><source>J&#x000a0;Am Coll Cardiol</source><volume>79</volume><issue>4</issue><year>2022</year><fpage>390</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2021.11.021</pub-id><pub-id pub-id-type="pmid">35086661</pub-id>
</element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Sequeira</surname><given-names>V.</given-names></name><name><surname>Maack</surname><given-names>C.</given-names></name><name><surname>Reil</surname><given-names>G.H.</given-names></name><name><surname>Reil</surname><given-names>J.C.</given-names></name></person-group><article-title>Exploring the connection between relaxed myosin states and the Anrep effect</article-title><source>Circ Res</source><volume>134</volume><issue>1</issue><year>2024</year><fpage>117</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1161/circresaha.123.323173</pub-id><pub-id pub-id-type="pmid">38175910</pub-id>
</element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>von Anrep</surname><given-names>G.</given-names></name></person-group><article-title>On the part played by the suprarenals in the normal vascular reactions of the body</article-title><source>J&#x000a0;Physiol</source><volume>45</volume><year>1912</year><fpage>307</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">16993158</pub-id>
</element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Sarnoff</surname><given-names>S.J.</given-names></name><name><surname>Mitchell</surname><given-names>J.H.</given-names></name><name><surname>Gilmore</surname><given-names>J.P.</given-names></name><name><surname>Remensnyder</surname><given-names>J.P.</given-names></name></person-group><article-title>Homeometric autoregulation in the heart</article-title><source>Circ Res</source><volume>8</volume><year>1960</year><fpage>1077</fpage><lpage>1091</lpage><pub-id pub-id-type="pmid">13746560</pub-id>
</element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Reil</surname><given-names>J.C.</given-names></name><name><surname>Reil</surname><given-names>G.H.</given-names></name><name><surname>Kov&#x000e1;cs</surname><given-names>&#x000c1;.</given-names></name><etal/></person-group><article-title>CaMKII activity contributes to homeometric autoregulation of the heart: a novel mechanism for the Anrep effect</article-title><source>J&#x000a0;Physiol</source><volume>598</volume><issue>15</issue><year>2020</year><fpage>3129</fpage><lpage>3153</lpage><pub-id pub-id-type="doi">10.1113/jp279607</pub-id><pub-id pub-id-type="pmid">32394454</pub-id>
</element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Ten Brinke</surname><given-names>E.A.</given-names></name><name><surname>Burkhoff</surname><given-names>D.</given-names></name><name><surname>Klautz</surname><given-names>R.J.</given-names></name><etal/></person-group><article-title>Single-beat estimation of the left ventricular end-diastolic pressure-volume relationship in patients with heart failure</article-title><source>Heart</source><volume>96</volume><issue>3</issue><year>2010</year><fpage>213</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1136/hrt.2009.176248</pub-id><pub-id pub-id-type="pmid">19875367</pub-id>
</element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Morbach</surname><given-names>C.</given-names></name><name><surname>Simon</surname><given-names>I.</given-names></name><name><surname>Danner</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Heart rate&#x02013;corrected systolic ejection time: population-based reference values and differential prognostic utility in acute heart failure</article-title><source>Eur Heart J Imaging Methods Pract</source><volume>1</volume><issue>2</issue><year>2023</year><object-id pub-id-type="publisher-id">qyad020</object-id><pub-id pub-id-type="doi">10.1093/ehjimp/qyad020</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Suga</surname><given-names>H.</given-names></name></person-group><article-title>Ventricular energetics</article-title><source>Physiol Rev</source><volume>70</volume><issue>2</issue><year>1990</year><fpage>247</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1152/physrev.1990.70.2.247</pub-id><pub-id pub-id-type="pmid">2181496</pub-id>
</element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Previs</surname><given-names>M.J.</given-names></name><name><surname>O'Leary</surname><given-names>T.S.</given-names></name><name><surname>Morley</surname><given-names>M.P.</given-names></name><etal/></person-group><article-title>Defects in the proteome and metabolome in human hypertrophic cardiomyopathy</article-title><source>Circ Heart Fail</source><volume>15</volume><issue>6</issue><year>2022</year><object-id pub-id-type="publisher-id">e009521</object-id><pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.121.009521</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Schuldt</surname><given-names>M.</given-names></name><name><surname>Pei</surname><given-names>J.</given-names></name><name><surname>Harakalova</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Proteomic and functional studies reveal detyrosinated tubulin as treatment target in sarcomere mutation-induced hypertrophic cardiomyopathy</article-title><source>Circ Heart Fail</source><volume>14</volume><issue>1</issue><year>2021</year><object-id pub-id-type="publisher-id">e007022</object-id><pub-id pub-id-type="doi">10.1161/circheartfailure.120.007022</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Nollet</surname><given-names>E.E.</given-names></name><name><surname>Duursma</surname><given-names>I.</given-names></name><name><surname>Rozenbaum</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Mitochondrial dysfunction in human hypertrophic cardiomyopathy is linked to cardiomyocyte architecture disruption and corrected by improving NADH-driven mitochondrial respiration</article-title><source>Eur Heart J</source><volume>44</volume><issue>13</issue><year>2023</year><fpage>1170</fpage><lpage>1185</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehad028</pub-id><pub-id pub-id-type="pmid">36734059</pub-id>
</element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Olivotto</surname><given-names>I.</given-names></name><name><surname>Girolami</surname><given-names>F.</given-names></name><name><surname>Sciagr&#x000e0;</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations</article-title><source>J&#x000a0;Am Coll Cardiol</source><volume>58</volume><year>2011</year><fpage>839</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2011.05.018</pub-id><pub-id pub-id-type="pmid">21835320</pub-id>
</element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>S.E.</given-names></name><name><surname>Jerosch-Herold</surname><given-names>M.</given-names></name><name><surname>Hudsmith</surname><given-names>L.E.</given-names></name><etal/></person-group><article-title>Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging</article-title><source>Circulation</source><volume>115</volume><issue>18</issue><year>2007</year><fpage>2418</fpage><lpage>2425</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.657023</pub-id><pub-id pub-id-type="pmid">17452610</pub-id>
</element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Crilley</surname><given-names>J.G.</given-names></name><name><surname>Boehm</surname><given-names>E.A.</given-names></name><name><surname>Blair</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy</article-title><source>J&#x000a0;Am Coll Cardiol</source><volume>41</volume><year>2003</year><fpage>1776</fpage><lpage>1782</lpage><pub-id pub-id-type="pmid">12767664</pub-id>
</element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Dass</surname><given-names>S.</given-names></name><name><surname>Cochlin</surname><given-names>L.E.</given-names></name><name><surname>Suttie</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Exacerbation of cardiac energetic impairment during exercise in hypertrophic cardiomyopathy: a potential mechanism for diastolic dysfunction</article-title><source>Cardiovas Res</source><volume>36</volume><year>2015</year><fpage>1547</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehv120</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Borlaug</surname><given-names>B.A.</given-names></name><name><surname>Kass</surname><given-names>D.A.</given-names></name></person-group><article-title>Invasive hemodynamic assessment in heart failure</article-title><source>Heart Fail Clin</source><volume>5</volume><issue>2</issue><year>2009</year><fpage>217</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.hfc.2008.11.008</pub-id><pub-id pub-id-type="pmid">19249690</pub-id>
</element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Timmer</surname><given-names>S.A.</given-names></name><name><surname>Knaapen</surname><given-names>P.</given-names></name><name><surname>Germans</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Effects of alcohol septal ablation on coronary microvascular function and myocardial energetics in hypertrophic obstructive cardiomyopathy</article-title><source>Am J Physiol Heart Circ Physiol</source><volume>301</volume><issue>1</issue><year>2011</year><fpage>H129</fpage><lpage>H137</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00077.2011</pub-id><pub-id pub-id-type="pmid">21490327</pub-id>
</element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>R.</given-names></name><name><surname>Guth</surname><given-names>B.D.</given-names></name><name><surname>Heusch</surname><given-names>G.</given-names></name></person-group><article-title>No effect of coronary perfusion on regional myocardial function within the autoregulatory range in pigs. Evidence against the Gregg phenomenon</article-title><source>Circulation</source><volume>83</volume><issue>4</issue><year>1991</year><fpage>1390</fpage><lpage>1403</lpage><pub-id pub-id-type="doi">10.1161/01.cir.83.4.1390</pub-id><pub-id pub-id-type="pmid">2013156</pub-id>
</element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>X.</given-names></name><name><surname>Anzai</surname><given-names>A.</given-names></name><name><surname>Katsumata</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction</article-title><source>J&#x000a0;Mol Cell Cardiol</source><volume>62</volume><year>2013</year><fpage>24</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2013.04.023</pub-id><pub-id pub-id-type="pmid">23644221</pub-id>
</element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Xu</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Characterization of early myocardial inflammation in ischemia-reperfusion injury</article-title><source>Front Immunol</source><volume>13</volume><year>2023</year><object-id pub-id-type="publisher-id">1081719</object-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1081719</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Scholtz</surname><given-names>S.</given-names></name><name><surname>Rudolph</surname><given-names>V.</given-names></name><name><surname>Reil</surname><given-names>J.C.</given-names></name></person-group><article-title>Alcohol septal ablation or mavacamten for obstructive hypertrophic cardiomyopathy</article-title><source>J&#x000a0;Clin Med</source><volume>12</volume><issue>20</issue><year>2023</year><object-id pub-id-type="publisher-id">6628</object-id><pub-id pub-id-type="doi">10.3390/jcm12206628</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Hatano</surname><given-names>A.</given-names></name><name><surname>Izu</surname><given-names>L.T.</given-names></name><name><surname>Chen-Izu</surname><given-names>Y.</given-names></name><name><surname>Sato</surname><given-names>D.</given-names></name></person-group><article-title>Modeling autoregulation of cardiac excitation-Ca-contraction and arrhythmogenic activities in response to mechanical load changes</article-title><source>iScience</source><volume>28</volume><year>2025</year><object-id pub-id-type="publisher-id">111788</object-id><pub-id pub-id-type="doi">10.1016/j.isci.2025.111788</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Sequeira</surname><given-names>V.</given-names></name><name><surname>Najafi</surname><given-names>A.</given-names></name><name><surname>Wijnker</surname><given-names>P.J.</given-names></name><etal/></person-group><article-title>ADP-stimulated contraction: a predictor of thin-filament activation in cardiac disease</article-title><source>Proc Natl Acad Sci USA</source><volume>112</volume><issue>50</issue><year>2015</year><fpage>E7003</fpage><lpage>E7012</lpage><pub-id pub-id-type="doi">10.1073/pnas.1513843112</pub-id><pub-id pub-id-type="pmid">26621701</pub-id>
</element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Sequeira</surname><given-names>V.</given-names></name><name><surname>Wijnker</surname><given-names>P.J.M.</given-names></name><name><surname>Nijenkamp</surname><given-names>L.L.A.M.</given-names></name><etal/></person-group><article-title>Perturbed length-sependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations</article-title><source>Circ Res</source><volume>112</volume><year>2013</year><fpage>1491</fpage><lpage>1505</lpage><pub-id pub-id-type="doi">10.1161/circresaha.111.300436</pub-id><pub-id pub-id-type="pmid">23508784</pub-id>
</element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Witjas-Paalberends</surname><given-names>E.R.</given-names></name><name><surname>G&#x000fc;&#x000e7;l&#x000fc;</surname><given-names>A.</given-names></name><name><surname>Germans</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations</article-title><source>Cardiovasc Res</source><volume>103</volume><year>2014</year><fpage>248</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvu127</pub-id><pub-id pub-id-type="pmid">24835277</pub-id>
</element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Sirenko</surname><given-names>S.G.</given-names></name><name><surname>Potter</surname><given-names>J.D.</given-names></name><name><surname>Knollmann</surname><given-names>B.C.</given-names></name></person-group><article-title>Differential effect of troponin T mutations on the inotropic responsiveness of mouse hearts - role of myofilament Ca<sup>2+</sup> sensitivity increase</article-title><source>J&#x000a0;Physiol</source><volume>575</volume><year>2006</year><fpage>201</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">16777946</pub-id>
</element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>R.L.</given-names></name><name><surname>Trivedi</surname><given-names>D.V.</given-names></name><name><surname>Sarkar</surname><given-names>S.S.</given-names></name><etal/></person-group><article-title>Deciphering the super relaxed state of human &#x003b2;-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers</article-title><source>Proc Natl Acad Sci</source><volume>115</volume><year>2018</year><fpage>E8143</fpage><lpage>E8152</lpage><pub-id pub-id-type="doi">10.1073/pnas.1809540115</pub-id><pub-id pub-id-type="pmid">30104387</pub-id>
</element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Gollapudi</surname><given-names>S.K.</given-names></name><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Gan</surname><given-names>Q.-F.</given-names></name><name><surname>Nag</surname><given-names>S.</given-names></name></person-group><article-title>Synthetic thick filaments: a new avenue for better understanding the myosin super-relaxed state in healthy, diseased, and mavacamten-treated cardiac systems</article-title><source>J&#x000a0;Biol Chem</source><volume>296</volume><year>2021</year><object-id pub-id-type="publisher-id">100114</object-id><pub-id pub-id-type="doi">10.1074/jbc.RA120.016506</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>C.Y.</given-names></name><name><surname>Mealiffe</surname><given-names>M.E.</given-names></name><name><surname>Bach</surname><given-names>R.G.</given-names></name><etal/></person-group><article-title>Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy</article-title><source>J&#x000a0;Am Coll Cardiol</source><volume>75</volume><issue>21</issue><year>2020</year><fpage>2649</fpage><lpage>2660</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2020.03.064</pub-id><pub-id pub-id-type="pmid">32466879</pub-id>
</element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Olivotto</surname><given-names>I.</given-names></name><name><surname>Oreziak</surname><given-names>A.</given-names></name><name><surname>Barriales-Villa</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial</article-title><source>Lancet</source><volume>396</volume><issue>10253</issue><year>2020</year><fpage>759</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(20)31792-x</pub-id><pub-id pub-id-type="pmid">32871100</pub-id>
</element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Hegde</surname><given-names>S.M.</given-names></name><name><surname>Lester</surname><given-names>S.J.</given-names></name><name><surname>Solomon</surname><given-names>S.D.</given-names></name><etal/></person-group><article-title>Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy</article-title><source>J&#x000a0;Am Coll Cardiol</source><volume>78</volume><issue>25</issue><year>2021</year><fpage>2518</fpage><lpage>2532</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2021.09.1381</pub-id><pub-id pub-id-type="pmid">34915982</pub-id>
</element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Germans</surname><given-names>T.</given-names></name><name><surname>R&#x000fc;ssel</surname><given-names>I.</given-names></name><name><surname>G&#x000f6;tte</surname><given-names>M.</given-names></name><etal/></person-group><article-title>How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance</article-title><source>J&#x000a0;Cardiovas Mag Res</source><volume>12</volume><year>2010</year><fpage>13</fpage></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Timmer</surname><given-names>S.A.J.</given-names></name><name><surname>Germans</surname><given-names>T.</given-names></name><name><surname>Brouwer</surname><given-names>W.P.</given-names></name><etal/></person-group><article-title>Carriers of the hypertrophic cardiomyopathy <italic>MYBPC3</italic> mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction</article-title><source>Eur Heart J</source><volume>13</volume><year>2011</year><fpage>1283</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1093/eurjhf/hfr135</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Biagini</surname><given-names>E.</given-names></name><name><surname>Coccolo</surname><given-names>F.</given-names></name><name><surname>Ferlito</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients</article-title><source>J&#x000a0;Am Coll Cardiol</source><volume>46</volume><year>2005</year><fpage>1543</fpage><lpage>1550</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2005.04.062</pub-id><pub-id pub-id-type="pmid">16226182</pub-id>
</element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>K.C.</given-names></name><name><surname>Geske</surname><given-names>J.B.</given-names></name><name><surname>Hebl</surname><given-names>V.B.</given-names></name><etal/></person-group><article-title>Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy</article-title><source>Eur Heart J Cardiovasc Imaging</source><volume>17</volume><issue>6</issue><year>2016</year><fpage>604</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1093/ehjci/jew024</pub-id><pub-id pub-id-type="pmid">26922089</pub-id>
</element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Neubauer</surname><given-names>S.</given-names></name><name><surname>Horn</surname><given-names>M.</given-names></name><name><surname>Pabst</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Contributions of 31P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease</article-title><source>Eur Heart J</source><volume>16</volume><year>1995</year><fpage>115</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/16.suppl_O.115</pub-id><pub-id pub-id-type="pmid">8682076</pub-id>
</element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>J.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Afterload mismatch and preload reserve: a conceptual framework for the analysis of ventricular function</article-title><source>Prog Cardiovasc Dis</source><volume>18</volume><issue>4</issue><year>1976</year><fpage>255</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1016/0033-0620(76)90021-9</pub-id><pub-id pub-id-type="pmid">128034</pub-id>
</element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>J.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Afterload mismatch in aortic and mitral valve disease: implications for surgical therapy</article-title><source>J&#x000a0;Am Coll Cardiol</source><volume>5</volume><issue>4</issue><year>1985</year><fpage>811</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1016/s0735-1097(85)80418-6</pub-id><pub-id pub-id-type="pmid">3882814</pub-id>
</element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Sherrid</surname><given-names>M.V.</given-names></name><name><surname>Balaran</surname><given-names>S.K.</given-names></name><name><surname>Korzeniecki</surname><given-names>E.</given-names></name><name><surname>Chaudhry</surname><given-names>F.A.</given-names></name><name><surname>Swistel</surname><given-names>D.G.</given-names></name></person-group><article-title>Reversal of acute systolic dysfunction and cardiogenic shock in hypertrophic cardiomyopathy by surgical relief of obstruction</article-title><source>Echocardiography</source><volume>28</volume><year>2011</year><fpage>E174</fpage><lpage>E179</lpage><pub-id pub-id-type="doi">10.1111/j.1540-8175.2011.01459.x</pub-id><pub-id pub-id-type="pmid">21801200</pub-id>
</element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Wachter</surname><given-names>R.</given-names></name><name><surname>Schmidt-Schweda</surname><given-names>S.</given-names></name><name><surname>Westermann</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Blunted frequency-dependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure</article-title><source>Eur Heart J</source><volume>30</volume><issue>24</issue><year>2009</year><fpage>3027</fpage><lpage>3036</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehp341</pub-id><pub-id pub-id-type="pmid">19720638</pub-id>
</element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgments</title><p id="p0155">The authors acknowledge support by the Open Access Publication Funds of the <funding-source id="gs5">Julius Maximilians University of W&#x000fc;rzburg and the Universit&#x000e4;tsklinikum W&#x000fc;rzburg</funding-source>.</p></ack><fn-group><fn id="d36e585"><p id="ntpara0015aa">The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors&#x02019; institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the <ext-link ext-link-type="uri" xlink:href="https://www.jacc.org/author-center" id="interref1">Author Center</ext-link>.</p></fn></fn-group></back></article>